Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;17(9):1156-1163.
doi: 10.1111/j.1468-1331.2010.02984.x. Epub 2010 Mar 22.

Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany

Y Winter  1 , M Balzer-Geldsetzer  1 , A Spottke  2 , J P Reese  1 , E Baum  3 , J Klotsche  4 , J Rieke  5 , A Simonow  6 , K Eggert  1 , W H Oertel  1 , R Dodel  1
Affiliations

Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany

Y Winter et al. Eur J Neurol. 2010 Sep.

Abstract

Objective: To determine the health economic burden on patients with Parkinson's disease (PD) in Germany over a 12-month observation period and provide a comprehensive analysis of cost-driving factors.

Methods and patients: Patients with PD (n = 145) were recruited from two clinical departments, two office-based neurologists and 12 GPs. Clinical evaluations were performed at baseline, 3, 6 and 12 months. Disease severity was measured using the Unified Parkinson's Disease Rating Scale (UPDRS). Cost data were assessed based on a patient diary and via personal structured interviews at the respective time-points. Costs were calculated from the societal perspective (2009 euro). Cost-driving factors were identified by multivariate regression analysis.

Results: Mean annual costs totalled euro20 095 per patient. Amongst direct costs, the highest expenditures (euro13 158) were for drugs (euro3526) and inpatient care including nursing homes (euro3789). Indirect costs accounted for 34.5% (euro6937) of total costs. Costs of home care provided by family accounted for 20% of direct costs. Cost-driving factors were identified for total costs (UPDRS, fluctuations, dyskinesia and younger age), direct costs (UPDRS, fluctuations), patient expenditures (UPDRS, depression) and drug costs (younger age).

Conclusion: Parkinson's disease has a chronic course with growing disability and considerable socioeconomic burden. Disease progression leads to an increasing number of patients who require costly institutionalized care. Home care is a major factor influencing patients' families. Healthcare programmes aimed at reducing the burden of PD on society and individuals should consider cost-driving factors of PD.

PubMed Disclaimer

References

    1. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord 2003; 18: 1139-1145.
    1. Whetten-Goldstein K, Sloan F, Kulas E, et al. . The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844-849.
    1. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics 1999; 16: 59-69.
    1. Muller T, Voss B, Hellwig K, Josef Stein F, Schulte T, Przuntek H. Treatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic. CNS Drugs 2004; 18: 105-111.
    1. Keller S, Kessler T, Meuser T, Fogel W, Bremen D, Jost WH. Analysis of direct costs in therapy of Parkinson disease. Nervenarzt 2003; 74: 1105-1109.

Publication types

MeSH terms

Substances